Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2022

Genmab — Januar 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • V Offline
    V Offline
    Vitus
    wrote on sidst redigeret af
    #58

    Og jeg beholder mine….jeg har jo læst Helges gode bog……

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #59

      Det gør den snart. Sidst i 21 eller lidt ind i 22 sagde Winkel på et tidspunkt. Med de fald vi har set, er et dårligt udfald sikkert allerede (delvist) indregnet.

      1 Reply Last reply
      0
      • V Offline
        V Offline
        Vitus
        wrote on sidst redigeret af
        #60

        Vi krydser alt hvad vi krydse kan Bulder..

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #61

          Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,200 at Bernstein https://www.avanza.se/placera/telegram/2022/01/04/genmab-bernstein-hojer-riktkursen-for-genmab-till-3-200-danska-kronor-3-150-upprepar-outperform-bn.html

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #62

            Novo og sundhedsaktier ramt af genåbningshåb vurderer strateg https://www.proinvestor.com/investornyt/758638/novo-og-sundhedsaktier-ramt-af-genabningshab-vurderer-strateg

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #63

              Genmab and Synaffix Enter into License Agreement for ADC Technology
              Media Release

              Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
              Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
              Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales

              1 Reply Last reply
              0
              • B Offline
                B Offline
                BioShare
                wrote on sidst redigeret af
                #64

                Genmab og Synaffix indgår aftale om ADC.

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  BioShare
                  wrote on sidst redigeret af
                  #65

                  https://ir.genmab.com/news-releases/news-release-details/genmab-and-synaffix-enter-license-agreement-adc-technology

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    ProinvestorNEWS
                    wrote on sidst redigeret af
                    #66

                    Genmab and Synaffix Enter into License Agreement for ADC Technology https://www.proinvestor.com/investornyt/758658/genmab-and-synaffix-enter-into-license-agreement-for-adc-technology

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #67

                      site specific conjugation bl.a.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #68

                        bl.a. ?

                        1 Reply Last reply
                        0
                        • M Offline
                          M Offline
                          Mcjean
                          wrote on sidst redigeret af
                          #69

                          onder andere

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #70

                            😉 ok

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #71

                              it isn't that long ago that Jan told us how impressed he was with AbbVie ADC technology, calling it ADC 3.0 ... things change fast i guess

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #72

                                Synaffix even partnered with ADCT ...

                                https://synaffix.com/

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #73

                                  https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies

                                  1 Reply Last reply
                                  0
                                  • troldmandenT Offline
                                    troldmandenT Offline
                                    troldmanden
                                    wrote on sidst redigeret af
                                    #74

                                    Det er ikke helt klart om de $415 mio er per target/antistof, eller om det er den øvre grænse for max x projekter

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      BioShare
                                      wrote on sidst redigeret af
                                      #75

                                      Det er "total potential deal value" + "tired mid-single digits royalty".

                                      1 Reply Last reply
                                      0
                                      • troldmandenT Offline
                                        troldmandenT Offline
                                        troldmanden
                                        wrote on sidst redigeret af
                                        #76

                                        ja men vi ved ikke hvor mange targetes der er tale om. Men egentligt kunne man (læs mig selv) også sige sig selv at der er tale om flere aftaler til det beløb. For der bliver ikke indgået SÅ store deals på enkelt target/antistof der først nu skal startes op. Altså bliver det ikke mere earlystage end det her

                                        1 Reply Last reply
                                        0
                                        • troldmandenT Offline
                                          troldmandenT Offline
                                          troldmanden
                                          wrote on sidst redigeret af
                                          #77

                                          Så vi taler nok 3-5 targets i alt

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper